EyeGene Stock

EyeGene OCF Margin

The Operating Cash Flow Margin of EyeGene (185490.KQ) as of Aug 5, 2026 is -167.69 %. In the previous year, Operating Cash Flow Margin was -362.70 % — a change of -53.77% (higher).

OCF Margin

-167.69 %

YoY

-53.77%

Last updated:

Operating Cash Flow Margin of EyeGene is 2026 -167.69 % . Operating Cash Flow Margin of EyeGene was 2025 -362.70 % . It decreases by -53.77% higher compared to the previous year.
Access this data via the Eulerpool API

EyeGene Stock analysis

What does EyeGene do? EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases. EyeGene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EyeGene stock

Operating Cash Flow Margin of EyeGene is -167.69 % in 2026.

Operating Cash Flow Margin of EyeGene changed from -362.70 % to -167.69 %, representing a -53.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin EyeGene since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's EyeGene with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — EyeGene

All Key Metrics — EyeGene